Smokers switching to Platform 1 were exposed to lower levels of harmful chemicals compared to those who continued smoking
The results of our NCT01970995 clinical study
Clinical Assessment is a key step in PMI’s scientific assessment of its smoke-free products for determining whether these products fulfil their goal. Dedicated Reduced Exposure studies verify whether smokers who switch to one of our smoke-free products are actually exposed to lower levels of harmful chemicals compared to smoking cigarettes.
Exposure to these chemicals can be assessed through measuring the levels of certain compounds, known as Biomarkers of Exposure, in the blood or urine of the subjects.
A recently published study of our program confirmed that levels of these biomarkers in participants switching completely to Platform 1 were comparable to the levels of those who quit smoking for the 90 days of the study.
In both cases, the levels of the biomarkers remained well below those observed in participants who continued smoking during the study.